Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 57 10 2020 04 22 581 585 Shahram Taheri Isfahan Kidney diseases research center/Department of Nephrology, Isfahan University of Medical Sciences, Isfahan, Iran. Ali Asghar Pilehvarian Department of Biology, Payame Noor University, Isfahan, Iran. Afsoon Emami Naeini Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Fariba Kushki Department of Biology, Payame Noor University, Isfahan, Iran. Firouzeh Moeinzadeh Department of Nephrology, Isfahan Kidney Diseases Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. 2019 11 23 2020 01 25 End-stage renal disease is a situation that predisposes the patients to cardiovascular disease, especially myocardial infarction (MI). A valuable biomarker for the diagnosis of this event is cardiac troponin. Although some asymptomatic patients show high plasma levels of cardiac troponin I, it is still the most sensitive variable in MI. All patients more than 18-year-old, on chronic ambulatory peritoneal dialysis (CAPD) for at least three months, and did not have a history of acute myocardial infarction or hospitalization for CVD during last month are included in a cross-sectional descriptive study. Troponin I serum level was measured by VIDAS Troponin I Ultra (TNIU) Assay.  Correlation between serum troponin level and cardiovascular risk factors are evaluated. In this study, 52% of patients were male. The mean cTnI level was 0.025±0.044 ng/mL, less than 0.11 ng/mL, and only five patients had cTnI level more than the laboratory threshold. The cut-off level of cTnI for diagnosing cardiovascular disease must be re-evaluated and maybe increase to 0.3 ng/mL. Indeed, the asymptomatic patient may need more close observation for cardiovascular disease. https://acta.tums.ac.ir/index.php/acta/article/view/8191 https://acta.tums.ac.ir/index.php/acta/article/download/8191/5325